Cargando…
合并MET基因变异的非小细胞肺癌治疗研究进展
Mesenchymal-epithelial transition factor (MET) has long been considered as the most crucial and promising driver gene in the occurrence and development of non-small cell lung cancer (NSCLC), except for epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and c-ROS oncogene 1 re...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
中国肺癌杂志编辑部
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9845091/ https://www.ncbi.nlm.nih.gov/pubmed/36617474 http://dx.doi.org/10.3779/j.issn.1009-3419.2022.101.54 |
_version_ | 1784870813108797440 |
---|---|
collection | PubMed |
description | Mesenchymal-epithelial transition factor (MET) has long been considered as the most crucial and promising driver gene in the occurrence and development of non-small cell lung cancer (NSCLC), except for epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and c-ROS oncogene 1 receptor tyrosine kinase (ROS1). In recent years, therapeutic drugs targeting MET have been continuously developed and applied in clinical practice. First, the curative effect of NSCLC patients with MET exon 14 skipping mutations has been further improved. In addition, when MET amplification occurs after resistance to EGFR tyrosine kinase inhibitors (EGFR-TKIs) in patients with advanced EGFR-mutant NSCLC, the combination of MET-TKIs and EGFR-TKIs has brought significant survival benefits and many other advances. This article reviews the treatment progress of NSCLC patients with different types of MET variants under different circumstances, which provides reference for the selection of clinical treatment strategies. |
format | Online Article Text |
id | pubmed-9845091 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | 中国肺癌杂志编辑部 |
record_format | MEDLINE/PubMed |
spelling | pubmed-98450912023-01-30 合并MET基因变异的非小细胞肺癌治疗研究进展 Zhongguo Fei Ai Za Zhi 综述 Mesenchymal-epithelial transition factor (MET) has long been considered as the most crucial and promising driver gene in the occurrence and development of non-small cell lung cancer (NSCLC), except for epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and c-ROS oncogene 1 receptor tyrosine kinase (ROS1). In recent years, therapeutic drugs targeting MET have been continuously developed and applied in clinical practice. First, the curative effect of NSCLC patients with MET exon 14 skipping mutations has been further improved. In addition, when MET amplification occurs after resistance to EGFR tyrosine kinase inhibitors (EGFR-TKIs) in patients with advanced EGFR-mutant NSCLC, the combination of MET-TKIs and EGFR-TKIs has brought significant survival benefits and many other advances. This article reviews the treatment progress of NSCLC patients with different types of MET variants under different circumstances, which provides reference for the selection of clinical treatment strategies. 中国肺癌杂志编辑部 2022-12-20 /pmc/articles/PMC9845091/ /pubmed/36617474 http://dx.doi.org/10.3779/j.issn.1009-3419.2022.101.54 Text en 版权所有©《中国肺癌杂志》编辑部2022 https://creativecommons.org/licenses/by/3.0/This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/. |
spellingShingle | 综述 合并MET基因变异的非小细胞肺癌治疗研究进展 |
title | 合并MET基因变异的非小细胞肺癌治疗研究进展 |
title_full | 合并MET基因变异的非小细胞肺癌治疗研究进展 |
title_fullStr | 合并MET基因变异的非小细胞肺癌治疗研究进展 |
title_full_unstemmed | 合并MET基因变异的非小细胞肺癌治疗研究进展 |
title_short | 合并MET基因变异的非小细胞肺癌治疗研究进展 |
title_sort | 合并met基因变异的非小细胞肺癌治疗研究进展 |
topic | 综述 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9845091/ https://www.ncbi.nlm.nih.gov/pubmed/36617474 http://dx.doi.org/10.3779/j.issn.1009-3419.2022.101.54 |
work_keys_str_mv | AT hébìngmetjīyīnbiànyìdefēixiǎoxìbāofèiáizhìliáoyánjiūjìnzhǎn AT hébìngmetjīyīnbiànyìdefēixiǎoxìbāofèiáizhìliáoyánjiūjìnzhǎn AT hébìngmetjīyīnbiànyìdefēixiǎoxìbāofèiáizhìliáoyánjiūjìnzhǎn AT hébìngmetjīyīnbiànyìdefēixiǎoxìbāofèiáizhìliáoyánjiūjìnzhǎn AT hébìngmetjīyīnbiànyìdefēixiǎoxìbāofèiáizhìliáoyánjiūjìnzhǎn |